fda tirzepatide news FDA's decision creates uncertainty for patients—and leads to a lawsuit FDA approves Zepbound for sleep

Frankly, one does not need a credential at all to offer unhelpful and shortsighted advice

In the ELIXA CVOT, lixisenatide was found to be non-inferior to standard of care plus placebo in terms of risk of the composite endpoint (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina)13.4% in the lixisenatide group and 13.2% in the placebo group (hazard ratio, 1.02

The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function

Retrieved from Gill, L

TGA complaints add to research suggesting the GLP-1 receptor agonists may be associated with ophthalmic complications